Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Filipits

Showing results (61-70 of 122) with videos related to

Pageof 13
Sort By:
The American Journal of Pathology|January 13, 2011
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysisGerold Bepler, Ken André Olaussen, Anne-Lise Vataire, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2011
Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapyMir Alireza Hoda, Amir Mohamed, Bahil Ghanim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2022
Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast CancerChristian F Singer, , Frederik Holst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapyMartin Filipits, Margaretha Rudas, Harald Heinzl, et al.
Stereotactic and Functional Neurosurgery|October 11, 2016
Gamma Knife Radiosurgery in Recurrent GlioblastomaJosa M Frischer, Christine Marosi, Adelheid Woehrer, et al.
Breast Cancer Research and Treatment|January 30, 2007
Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancerGerwin Heller, Joseph Geradts, Barbara Ziegler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic ProgramMartin Filipits, Vincent Haddad, Katharina Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancerNermine S Kamal, Jean-Charles Soria, Jean Mendiboure, et al.
Molecular Oncology|February 6, 2014
Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancerXiaoli Ma, Vanessa Rousseau, Haiji Sun, et al.
Breast Cancer Research and Treatment|May 2, 2019
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy aloneIvana Sestak, Miguel Martín, Peter Dubsky, et al.
Pageof 13

Showing results (61-70 of 122) with videos related to

Sort By:
Pageof 13
The American Journal of Pathology|January 13, 2011
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysisGerold Bepler, Ken André Olaussen, Anne-Lise Vataire, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2011
Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapyMir Alireza Hoda, Amir Mohamed, Bahil Ghanim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2022
Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast CancerChristian F Singer, , Frederik Holst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapyMartin Filipits, Margaretha Rudas, Harald Heinzl, et al.
Stereotactic and Functional Neurosurgery|October 11, 2016
Gamma Knife Radiosurgery in Recurrent GlioblastomaJosa M Frischer, Christine Marosi, Adelheid Woehrer, et al.
Breast Cancer Research and Treatment|January 30, 2007
Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancerGerwin Heller, Joseph Geradts, Barbara Ziegler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic ProgramMartin Filipits, Vincent Haddad, Katharina Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancerNermine S Kamal, Jean-Charles Soria, Jean Mendiboure, et al.
Molecular Oncology|February 6, 2014
Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancerXiaoli Ma, Vanessa Rousseau, Haiji Sun, et al.
Breast Cancer Research and Treatment|May 2, 2019
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy aloneIvana Sestak, Miguel Martín, Peter Dubsky, et al.
Pageof 13